Could a common blood pressure pill shield the bladder from radiation damage?

NCT ID NCT05530655

Recruiting now Prevention Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This early-phase study is testing whether lisinopril, a widely used blood pressure drug, can prevent urinary side effects in men receiving radiation for prostate cancer. Thirty men with non-metastatic prostate cancer will take one of three daily doses (5, 10, or 20 mg) during their radiation treatment. Researchers will track urinary symptoms and biomarkers to find the safest and most promising dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lisinopril (an ACE inhibitor, a blood pressure drug)
What this could lead to: If it works, this could point toward a simple, low-cost way to prevent urinary problems after prostate radiation.
What could go wrong: This is a very early, small study (30 men) testing only dose safety and tolerability. It is not designed to prove effectiveness, and the drug may not reduce urinary side effects at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer radiation injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER RADIATION TOXICITY URINARY COMPLICATION

Contacts and locations

Locations

Wilmot Cancer Institute
RECRUITING

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.